Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study

Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study

Blog Article

We conducted a prospective study to evaluate immune responses to SARS-CoV-2 in oncology workers in which we collected blood and clinical data every 6 months.Spike-specific CD4+ T-cells and immunoglobulin G responses were measured using interferon-gamma enzyme-linked click here immunosorbent spot and enzyme-linked immunosorbent assay, respectively.Sixty (81%) vaccinated and 14 (19%) unvaccinated individuals were enrolled.CD4+ T-cell responses of those individuals currently naturally infected were comparable to those who were 6 months from receiving their last dose of the vaccine; both responses were significantly higher than among those who were unvaccinated.Unvaccinated participants who became vaccinated while in the study showed a significant increase in both types of spike-specific immune responses.

Previously vaccinated individuals who received a third dose (booster) showed a similar response to the spike protein.However, this response decreases as soon as 3 months but does not dip below the established response following two doses.Response to variants of concern princess polly dresses long sleeve B.1.617.

2 (Delta) and B.1.1.529 (Omicron) also increased, with the Omicron variant having a significantly lower response when compared to Delta and the wild type.We conclude that antibody and T-cell responses increase in oncology workers after serial vaccination but can wane over time.